Vincerx Pharma, Inc. (VINC) Income Statement
VINC 2024 at a glance
Fiscal year ended December 31, 2024 · U.S. dollarsVINC revenue and net income
VINC growth rates
to 2024| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VINC quarterly EPS vs estimates
Vincerx Pharma beat the analyst EPS estimate in 2 of the last 8 quarters.
VINC income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.1M | $915,000 | $939,000 | $340,000 | $172,996 | $172,996 |
| Gross profit | −$1.1M | −$915,000 | −$939,000 | −$340,000 | −$172,996 | −$172,996 |
| Research & development | $15.5M | $28.1M | $52.2M | $40.1M | $7.1M | — |
| Sales, general & admin | $16.0M | $13.6M | $19.0M | $22.6M | $3.6M | $54,000 |
| Total operating expenses | $31.5M | $41.7M | $71.1M | $62.7M | $10.7M | $45,000 |
| Operating income | −$31.5M | −$42.6M | −$68.7M | −$62.7M | −$10.7M | −$45,000 |
| Interest income | $472,000 | $1.5M | $664,000 | $0 | — | — |
| Interest expense | — | — | $8.2M | $23.4M | $8,000 | $0 |
| Income before taxes | −$30.1M | −$40.2M | −$63.0M | −$39.3M | −$10.7M | −$45,000 |
| Income taxes | — | — | −$8.2M | −$23.7M | $8,000 | −$54 |
| Net income | −$30.1M | −$40.2M | −$65.4M | −$39.3M | −$10.7M | −$54,000 |
| EBITDA | −$31.5M | −$39.2M | −$62.0M | −$39.0M | −$10.7M | $9,000 |
| EPS (diluted) | −$22.89 | −$37.73 | −$34.90 | −$36.46 | −$2.38 | $0.00 |
| Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.1M | $0 | $0 | $0 | $1.3M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $281,000 | $275,000 | $270,000 | $264,000 | $258,000 | $254,000 | $249,000 | $154,000 | $241,000 | $236,000 | $232,000 |
| Gross profit | — | $534,000 | −$275,000 | −$270,000 | −$264,000 | $1.1M | −$254,000 | −$249,000 | −$154,000 | −$241,000 | −$236,000 | −$232,000 |
| Research & development | $1.0M | $3.3M | $3.9M | $3.8M | $4.3M | $3.5M | $6.8M | $7.9M | $10.6M | $11.4M | $11.1M | $13.7M |
| Sales, general & admin | $2.3M | $5.6M | $3.9M | $3.6M | $2.9M | $1.8M | $3.5M | $3.8M | $4.5M | $4.0M | $4.5M | $4.7M |
| Total operating expenses | $3.3M | $8.8M | $7.8M | $7.4M | $7.2M | $5.5M | $10.3M | $11.7M | $15.1M | $15.4M | $15.6M | $18.5M |
| Operating income | −$3.3M | −$8.8M | −$7.8M | −$7.4M | −$7.5M | −$5.5M | −$10.3M | −$11.7M | −$15.1M | −$15.4M | −$16.9M | −$19.6M |
| Interest income | $0 | $62,000 | $154,000 | $157,000 | $99,000 | $198,000 | $260,000 | $327,000 | $466,000 | $460,000 | $204,000 | — |
| Interest expense | — | — | — | — | — | $758,000 | — | — | $758,000 | $8.2M | $22,000 | $1.2M |
| Income before taxes | −$5.0M | −$8.0M | −$7.8M | −$1.8M | −$12.4M | −$5.0M | −$9.7M | −$11.2M | −$14.3M | −$13.6M | −$16.9M | −$18.4M |
| Income taxes | — | −$220,724 | — | — | $220,724 | $1.6M | −$372,000 | −$458,000 | −$758,000 | −$8.2M | −$22,000 | −$1.2M |
| Net income | −$5.0M | −$8.0M | −$7.8M | −$1.8M | −$12.4M | −$5.0M | −$9.7M | −$11.2M | −$13.6M | −$5.5M | −$16.9M | −$17.2M |
| EBITDA | −$3.3M | −$8.5M | −$7.5M | −$7.1M | −$7.2M | −$5.3M | −$10.1M | −$11.8M | −$15.3M | −$15.2M | −$15.4M | −$18.2M |
| EPS (diluted) | −$3.57 | −$15.22 | −$3.40 | −$3.69 | −$0.58 | −$4.55 | −$9.21 | −$10.37 | −$13.60 | −$0.65 | −$14.77 | −$18.69 |
| Gross margin | — | 50.0% | — | — | — | 80.4% | — | — | — | — | — | — |
| Operating margin | — | −826.4% | — | — | — | −421.1% | — | — | — | — | — | — |
| Net margin | — | −748.5% | — | — | — | −376.7% | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VINC's financial statements (latest annual report filed March 27, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VINC financial results
Vincerx Pharma reported no revenue in fiscal year 2024 (ended December 31, 2024). It had a net loss of $30.1 million. Diluted earnings per share came to −$22.89.
See the VINC stock overview for the latest quote and news, or the VINC chart for price history and technical indicators.
VINC income statement FAQ
Does Vincerx Pharma have revenue?
Vincerx Pharma reported no revenue for fiscal year 2024, which ended on December 31, 2024.
Is Vincerx Pharma profitable?
No. Vincerx Pharma reported a net loss of $30.1 million in fiscal 2024.
How much does Vincerx Pharma spend on research and development?
Vincerx Pharma spent $15.5 million on research and development in fiscal 2024.
What are Vincerx Pharma's earnings per share?
Vincerx Pharma earned $-22.89 per diluted share in fiscal 2024, compared with $-37.73 a year earlier.
When does Vincerx Pharma's fiscal year end?
Vincerx Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2024 and was filed on March 27, 2025.